155 related articles for article (PubMed ID: 24954008)
21. Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase.
Santa Maria JP; Park Y; Yang L; Murgolo N; Altman MD; Zuck P; Adam G; Chamberlin C; Saradjian P; Dandliker P; Boshoff HIM; Barry CE; Garlisi C; Olsen DB; Young K; Glick M; Nickbarg E; Kutchukian PS
ACS Chem Biol; 2017 Sep; 12(9):2448-2456. PubMed ID: 28806050
[TBL] [Abstract][Full Text] [Related]
22. Enhanced in vitro activity of dihydrofolate reductase and dihydropteroase synthase inhibitors in combination against Nocardia spp.
Thielking DM; Destefano MS; Cynamon MH; Yeo AE
Antimicrob Agents Chemother; 2003 Mar; 47(3):1174. PubMed ID: 12604567
[No Abstract] [Full Text] [Related]
23. Inhibitors of de novo folate enzymes in Plasmodium falciparum.
Nzila A
Drug Discov Today; 2006 Oct; 11(19-20):939-44. PubMed ID: 16997145
[TBL] [Abstract][Full Text] [Related]
24. Regulation of one-carbon metabolism in Arabidopsis: the N-terminal regulatory domain of cystathionine gamma-synthase is cleaved in response to folate starvation.
Loizeau K; Gambonnet B; Zhang GF; Curien G; Jabrin S; Van Der Straeten D; Lambert WE; Rébeillé F; Ravanel S
Plant Physiol; 2007 Oct; 145(2):491-503. PubMed ID: 17720756
[TBL] [Abstract][Full Text] [Related]
25. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
26. Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis.
Hajian B; Scocchera E; Keshipeddy S; G-Dayanandan N; Shoen C; Krucinska J; Reeve S; Cynamon M; Anderson AC; Wright DL
PLoS One; 2016; 11(8):e0161740. PubMed ID: 27580226
[TBL] [Abstract][Full Text] [Related]
27. Comparative protein modeling of methionine S-adenosyltransferase (MAT) enzyme from Mycobacterium tuberculosis: a potential target for antituberculosis drug discovery.
Khedkar SA; Malde AK; Coutinho EC
J Mol Graph Model; 2005 Jan; 23(4):355-66. PubMed ID: 15670956
[TBL] [Abstract][Full Text] [Related]
28. Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets.
Assaraf YG; Ifergan I; Kadry WN; Pinter RY
J Theor Biol; 2006 Jun; 240(4):637-47. PubMed ID: 16352313
[TBL] [Abstract][Full Text] [Related]
29. Structure-based design of a potent and selective small peptide inhibitor of Mycobacterium tuberculosis 6-hydroxymethyl-7, 8-dihydropteroate synthase: a computer modelling approach.
Rao GS; Kumar M
Chem Biol Drug Des; 2008 Jun; 71(6):540-5. PubMed ID: 18482337
[TBL] [Abstract][Full Text] [Related]
30. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria.
Rengarajan J; Sassetti CM; Naroditskaya V; Sloutsky A; Bloom BR; Rubin EJ
Mol Microbiol; 2004 Jul; 53(1):275-82. PubMed ID: 15225321
[TBL] [Abstract][Full Text] [Related]
31. Kinetic modeling of tricarboxylic acid cycle and glyoxylate bypass in Mycobacterium tuberculosis, and its application to assessment of drug targets.
Singh VK; Ghosh I
Theor Biol Med Model; 2006 Aug; 3():27. PubMed ID: 16887020
[TBL] [Abstract][Full Text] [Related]
32. A novel inhibitor of indole-3-glycerol phosphate synthase with activity against multidrug-resistant Mycobacterium tuberculosis.
Shen H; Wang F; Zhang Y; Huang Q; Xu S; Hu H; Yue J; Wang H
FEBS J; 2009 Jan; 276(1):144-54. PubMed ID: 19032598
[TBL] [Abstract][Full Text] [Related]
33. Crystal structure of Mycobacterium tuberculosis 7,8-dihydropteroate synthase in complex with pterin monophosphate: new insight into the enzymatic mechanism and sulfa-drug action.
Baca AM; Sirawaraporn R; Turley S; Sirawaraporn W; Hol WG
J Mol Biol; 2000 Oct; 302(5):1193-212. PubMed ID: 11007651
[TBL] [Abstract][Full Text] [Related]
34. Binding mode analysis of 2,4-diamino-5-methyl-5-deaza-6-substituted pteridines with Mycobacterium tuberculosis and human dihydrofolate reductases.
da Cunha EF; Ramalho TC; Reynolds RC
J Biomol Struct Dyn; 2008 Feb; 25(4):377-85. PubMed ID: 18092832
[TBL] [Abstract][Full Text] [Related]
35. Mycobacterium tuberculosis dihydrofolate reductase reveals two conformational states and a possible low affinity mechanism to antifolate drugs.
Dias MV; Tyrakis P; Domingues RR; Paes Leme AF; Blundell TL
Structure; 2014 Jan; 22(1):94-103. PubMed ID: 24210757
[TBL] [Abstract][Full Text] [Related]
36. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
37. Folate and antifolate pharmacology.
Kamen B
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019
[TBL] [Abstract][Full Text] [Related]
38. Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis.
Wolff KA; Nguyen L
Expert Rev Anti Infect Ther; 2012 Sep; 10(9):971-81. PubMed ID: 23106273
[TBL] [Abstract][Full Text] [Related]
39. Essential roles of methionine and S-adenosylmethionine in the autarkic lifestyle of Mycobacterium tuberculosis.
Berney M; Berney-Meyer L; Wong KW; Chen B; Chen M; Kim J; Wang J; Harris D; Parkhill J; Chan J; Wang F; Jacobs WR
Proc Natl Acad Sci U S A; 2015 Aug; 112(32):10008-13. PubMed ID: 26221021
[TBL] [Abstract][Full Text] [Related]
40. Comparative effects of folate antagonists versus enzymatic folate depletion on folate and thymidine enzymes in cultured mammalian cells.
Chello PL; McQueen CA; DeAngelis LM; Bertino JR
Cancer Treat Rep; 1977 Jul; 61(4):539-48. PubMed ID: 195727
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
